Sirtuin modulating compounds

Patent Number: 7,345,178

This patent covers the composition of matter for novel compounds that are useful for modulation of sirtuins. Sirtuins are a class of proteins that act as histone deacetylase inhibitors. Why there is great interest in modulating these enzymes is because the SIR2 members of this family have been demonstrated to play a critical role in life extension associated with caloric restriction.

This patent is assigned to the company Sirtris, which recently went public and currently has a market cap of about $300 million. A formulation of resveratrol is the company's lead candidate, which already has entered clinical trials. Sirtris announced in a recent press release that they will begin clinical trials in 2008 using the new chemical entity covered by the current patent.

View this patent on the USPTO website.